» Articles » PMID: 11024124

Cells Expressing the Epstein-Barr Virus Growth Program Are Present in and Restricted to the Naive B-cell Subset of Healthy Tonsils

Overview
Journal J Virol
Date 2000 Oct 12
PMID 11024124
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

In this paper we demonstrate, for the first time, that Epstein-Barr virus (EBV)-infected cells expressing the lymphoblastoid growth program are present in healthy carriers of the virus. Previously we observed that latently infected naive B cells are present in tonsils only when viral replication is detected, suggesting that these may represent newly infected B cells. We have tested this idea by performing a reverse transcription-PCR analysis for the expression of latent genes (EBNA2 and the EBNA3s) that are characteristically expressed only by newly infected cells expressing the growth latency program. EBNA2 expression is regularly detected in purified naive (IgD(+)) tonsillar B cells (13 of 16 tonsils tested) but was never found in the IgD(-) population (0 of 16). More detailed analysis revealed that the mRNAs for the latent genes EBNA1 (3 of 3 tonsils tested), EBNA3a (3 of 5), EBNA3b (3 of 5), EBNA3c (3 of 5), LMP1 (6 of 6), and LMP2 (5 of 6) were also present in the IgD(+) population, but the EBNA1Q-K transcript, characteristic of nonlymphoblastoid forms of latency, was never detected (0 of 6). Finally, we demonstrate that the latently infected naive (IgD(+)) cells express CD80 (B7.1), a marker characteristically expressed on activated naive lymphoblasts but absent from resting naive B cells. The infected naive (IgD(+)) population in the tonsil therefore has the viral and cellular phenotype of a B-cell directly infected with EBV-an activated lymphoblast expressing the growth program.

Citing Articles

IL-8 Secreted by Gastric Epithelial Cells Infected with CagA Positive Strains Is a Chemoattractant for Epstein-Barr Virus Infected B Lymphocytes.

Dominguez-Martinez D, Fontes-Lemus J, Garcia-Regalado A, Juarez-Flores A, Fuentes-Panana E Viruses. 2023; 15(3).

PMID: 36992360 PMC: 10054738. DOI: 10.3390/v15030651.


IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease.

Mestecky J, Julian B, Raska M Front Immunol. 2023; 14:1085922.

PMID: 36865536 PMC: 9973316. DOI: 10.3389/fimmu.2023.1085922.


Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection.

Munz C Biomolecules. 2022; 12(1).

PMID: 35053187 PMC: 8774114. DOI: 10.3390/biom12010038.


The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia and Obstructive Sleep Apnea.

Carrasco A, Sjolander I, Van Acker A, Dernstedt A, Fehrm J, Forsell M Front Immunol. 2021; 12:674080.

PMID: 34745084 PMC: 8570126. DOI: 10.3389/fimmu.2021.674080.


M1 Macrophage Polarization Prevails in Epstein-Barr Virus-Infected Children in an Immunoregulatory Environment.

Moyano A, Ferressini Gerpe N, De Matteo E, Preciado M, Chabay P J Virol. 2021; 96(1):e0143421.

PMID: 34643432 PMC: 8754231. DOI: 10.1128/JVI.01434-21.


References
1.
Kurth J, Spieker T, Wustrow J, Strickler G, Hansmann L, Rajewsky K . EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity. 2000; 13(4):485-95. DOI: 10.1016/s1074-7613(00)00048-0. View

2.
Thorley-Lawson D, Babcock G . A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 1999; 65(14):1433-53. DOI: 10.1016/s0024-3205(99)00214-3. View

3.
Thorley-Lawson D, Mann K . Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med. 1985; 162(1):45-59. PMC: 2187697. DOI: 10.1084/jem.162.1.45. View

4.
Freedman A, Freeman G, Horowitz J, Daley J, Nadler L . B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol. 1987; 139(10):3260-7. View

5.
Young L, Dawson C, Clark D, Rupani H, Busson P, Tursz T . Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988; 69 ( Pt 5):1051-65. DOI: 10.1099/0022-1317-69-5-1051. View